This study aimed to evaluate the clinical efficacy of apatinib combined with capecitabine in advanced triple-negative breast cancer patients who failed second-line treatment.
From October 2015 to April 2017, we retrospectively screened 53 patients who had been diagnosed with advanced triple-negative breast cancer in our hospital. Experimental group: 26 patients with apatinib (250 mg, qd, orally) and capecitabine (1250mg/m2, bid, d1-14, orally), treatment was continued until disease progression. Control group :27 patients with capecitabine (1250mg/m2, bid, d1-14, orally). The objective response rate, disease control rate and adverse events of the two groups were compared.
The objective response rate and disease control rate in the experimental group was significantly higher than in the control group. The objective response rateswere 30.8% and 3.7%, respectively. The disease control rates were 65.4% and 29.6%, respectively. There were no significant differences in the adverse events between the two groups except grade I-II hypertension and I-II bleeding.
Apatinib combined with capecitabine is efficacious in treating patients with triple-negative breast cancer who failed second-line treatment, with acceptable toxic effects.
Clinical trial identification
Legal entity responsible for the study
Has not received any funding.
All authors have declared no conflicts of interest.